Early and late toxicity of radioiodine therapy: Detection and management

Endocrine Practice

Volumn 16, Issue 6, 2010, Pages 1064-1070

  Hyer, Steve L ^a   Newbold, Kate ^b   Harmer, Clive L ^b  

^a EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTITHYROID AGENT; ASCORBIC ACID; DEXAMETHASONE; FOLLITROPIN; IODINE 131; PREDNISOLONE; THIAMAZOLE;

AMENORRHEA; BONE MARROW TOXICITY; BRAIN METASTASIS; CELL NUCLEUS; CONGENITAL MALFORMATION; CORTICOSTEROID THERAPY; DACRYOCYSTORHINOSTOMY; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG MEGADOSE; DRUG UPTAKE; EARLY DIAGNOSIS; ENDOCRINE OPHTHALMOPATHY; EPIPHORA; FEMALE INFERTILITY; FETOTOXICITY; FLUID INTAKE; FOLLITROPIN BLOOD LEVEL; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOGEUSIA; INTERMETHOD COMPARISON; LACRIMAL DUCT; LACRIMAL DUCT OCCLUSION; LACRIMAL GLAND; LEUKEMIA; LUNG FUNCTION TEST; LUNG METASTASIS; MASSAGE; MEDICAL LITERATURE; MEDLINE; MENSTRUAL IRREGULARITY; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; RADIATION PNEUMONIA; RADIATION THYROIDITIS; RADIOACTIVITY; RADIOISOTOPE THERAPY; REVIEW; SALIVARY GLAND; SIALOADENITIS; SIALOGRAPHY; SIDE EFFECT; SPINAL CORD METASTASIS; SYSTEMATIC REVIEW; THYROID CANCER; THYROID DISEASE; THYROID DYSGENESIS; THYROIDECTOMY; THYROIDITIS; TREATMENT CONTRAINDICATION; XEROSTOMIA;

GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; THYROID DISEASES; THYROID GLAND; THYROID NEOPLASMS;

EID: 79952433962     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP10170.RA     Document Type: Review

References (31)

1. Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radiol). 2007;19:83-86. (Pubitemid 46044071)
2. Raza H, Khan AU, Hameed A, Khan A. Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy. Nucl Med Commun. 2006;27:495-499. (Pubitemid 44309710)
3. Liu B, Kuang A, Huang R, et al. Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial. J Nucl Med. 2010;51:618-623.
4. Nakada K, Ishibashi T, Takei T, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med. 2005;46:261-266.
5. Bohuslavizki KH, Klutmann S, Brenner W, et al. Radioprotection of salivary glands by amifostine in highdose radioiodine treatment: results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer. Strahlenther Onkol. 1999;175(suppl 4):6-12. (Pubitemid 29526270)
6. Brockmann H, Wilhelm K, Joe A, Palmedo H, Biersack HJ. Nasolacrimal drainage obstruction after radioiodine therapy: case report and a review of the literature. Clin Nucl Med. 2005;30:543-545. (Pubitemid 41026197)
7. Exss R, Graewe B. Congenital athyroidism in the newborn infant from intra-uterine radioiodine action. Biol Neonate. 1974;24:289-291.
8. Richards GE, Brewer ED, Conley SB, Saldana LR. Combined hypothyroidism and hypoparathyroidism in an infant after maternal 131I administration. J Pediatr. 1981;99:141-143. (Pubitemid 11046441)
9. Zanzonico PB. Radiation dose to patients and relatives incident to 131I therapy. Thyroid. 1997;7:199-204. (Pubitemid 27190580)
10. Gorman CA. Radioiodine and pregnancy. Thyroid. 1999;9:721-726. (Pubitemid 29357917)
11. Royal College of Physicians. Radioiodine in the Management of Benign Thyroid Disease: Clinical Guidelines; Report of a Working Party 2007. London, UK: Royal College of Physicians of London. June 2007. ISBN 9781860162978. http://bookshop.rcplondon.ac.uk/details.aspx?e=208. Accessed for verification October 27, 2010.
12. Baskin HJ, Cobin RH, Duick DS, et al (American Association of Clinical Endocrinologists). American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002;8:457-469.
13. Schlumberger M, De Vathaire F, Ceccarelli C, et al. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med. 1996;37:606-612. (Pubitemid 126618448)
14. McDermott MT, Kidd GS, Dodson LE Jr, Hofeldt FD. Radioiodine-induced thyroid storm: case report and literature review. Am J Med. 1983;75:353-359. (Pubitemid 13030880)
15. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med. 1989;321:1349-1352. (Pubitemid 19284190)
16. Tallstedt L, Lundell G, Tørring O (Thyroid Study Group). Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med. 1992;326:1733-1738.
17. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med. 1998;338:73-78. (Pubitemid 28042269)
18. Vini L, Hyer S, Al Saadi A, Pratt B, Harmer C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J. 2002;78:92-93. (Pubitemid 34112343)
19. Ceccarelli C, Bencivelli W, Morciano D, Pinchera A, Pacini F. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab. 2001;86:3512-3515. (Pubitemid 32755937)
20. Flux GD, Haq M, Chittenden SJ, et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37:270-275.
21. Hyer S, Vini L, O'Connell M, Pratt B, Harmer C. Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin Endocrinol (Oxf). 2002;56:755-758.
22. Krassas GE, Perros P. Thyroid disease and male reproductive function. J Endocrinol Invest. 2003;26:372-380. (Pubitemid 36763699)
23. Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med. 2003;44:451-456. (Pubitemid 39586024)
24. Alevizaki C, Molfetas M, Samartzis A, et al. Iodine 131 treatment for differentiated thyroid carcinoma in patients with end stage renal failure: dosimetric, radiation safety, and practical considerations. Hormones (Athens). 2006;5:276-287.
25. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962;87:171-182.
26. Maxon HR III, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am. 1990;19:685-718. (Pubitemid 20282663)
27. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89:1638-1644. (Pubitemid 37464133)
28. Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009;19:451-457.
29. Rall JE, Alpers JB, Lewallen CG, Sonenberg M, Berman M, Rawson RW. Radiation pneumonitis and fibrosis: a complication of radioiodine treatment of pulmonary metastases from cancer of the thyroid. J Clin Endocrinol Metab. 1957;17:1263-1276.
30. Hjiyiannakis P, Jefferies S, Harmer CL. Brain metastases in patients with differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol). 1996;8:327-330. (Pubitemid 26382031)
31. Jönsson H, Mattsson S. Excess radiation absorbed doses from non-optimised radioiodine treatment of hyperthyroidism. Radiat Prot Dosimetry. 2003;108:107-114.